We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prognostic Test Identifies Patients at High Risk of Developing Severe Preeclampsia

By LabMedica International staff writers
Posted on 17 Feb 2025

Preeclampsia is characterized by the onset of hypertension and proteinuria after 20 weeks of gestation, or in the absence of proteinuria, by new-onset hypertension accompanied by any of the following: thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, or new-onset headache unresponsive to medication. More...

Symptoms of preeclampsia, such as headaches, visual disturbances, epigastric pain, and shortness of breath, often go unnoticed and can have severe, lasting effects on both mothers and babies if not properly managed. These impacts may include maternal organ damage, an increased risk of future heart failure, preterm birth, and avoidable mental trauma. In the U.S., preeclampsia has risen by 25% in the past two decades and is a leading cause of maternal and fetal illness and death. Black women, in particular, face higher rates of maternal and adverse fetal and neonatal outcomes compared to other racial and ethnic groups, and they are at a greater risk of developing hypertensive disorders during pregnancy.

The only cure for preeclampsia is the removal of the placenta at delivery. The clinical presentation and progression of preeclampsia can vary greatly, making prediction, diagnosis, and monitoring difficult. Hospitalization is generally recommended to assess the potential for progression to severe disease. Traditional diagnostic markers for preeclampsia are often nonspecific and may not accurately predict the severity of the condition or associated adverse outcomes in the following days and weeks. There is a significant need for more reliable tools to manage severe preeclampsia. Identifying women at high risk for developing severe preeclampsia can lead to better prediction, earlier intervention, and reduced negative outcomes.

Roche (Basel, Switzerland) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a prognostic test designed to classify hospitalized pregnant women with hypertensive disorders into low- and high-risk categories for developing severe preeclampsia within two weeks of testing. The test measures the ratio of two key biomarkers, sFlt-1 and PlGF, which are involved in the formation of blood vessels during pregnancy. An imbalance of these biomarkers is known to play a crucial role in the development of preeclampsia. Their concentrations in maternal serum change before the disease manifests, making them useful for predicting the progression of preeclampsia. Nearly 70% of women with a sFlt-1/PlGF ratio greater than 38 delivered their babies within two weeks.

With the FDA clearance of the sFlt-1/PlGF ratio test on Roche platforms, clinicians now have an additional tool to identify women at the highest risk for developing severe preeclampsia. This biomarker test could drive innovation in developing new therapies for these patients. The preeclampsia ratio reflects Roche's commitment to advancing science to create transformative solutions that improve patient outcomes and streamline laboratory operations. Roche’s extensive U.S. installation base of over 4,000 cobas analyzers, combined with a high degree of menu consolidation across various indications, enables clinicians to make faster, more efficient clinical decisions, and rapidly scale testing for even more women.

"There is a great need for highly reliable tools, such as the Elecsys sFlt-1/PlGF ratio, to address severe preeclampsia," said Brad Moore, president and CEO of Roche Diagnostics North America. "We are eager to partner with our customers so this prognostic test can help clinicians plan care and improve patient outcomes."


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.